Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime Versus Cypher Select Stents; SEVEN-Xience Study

Trial Profile

Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime Versus Cypher Select Stents; SEVEN-Xience Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jul 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary) ; Everolimus (Primary) ; Pravastatin; Sirolimus
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Dyslipidaemias
  • Focus Therapeutic Use
  • Acronyms SEVEN-Xience
  • Most Recent Events

    • 25 Jul 2016 Status changed from recruiting to completed.
    • 27 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top